Genmab — November 2013
-
indtil videre har Janssen ikke haft en krone oppe af lommen (regnskabsmæssigt) på dara dealen. De må snart gerne vise, at det er for alvor
-
det kunne være en mulighed
-
-
er HSBC's opkøbsforsøg gået i sig selv igen?
-
-
Der bliver varmet om til ASH og det store showdown i CLL markedet - her er lidt baggrund på de forskellige spillere: http://seekingalpha.com/article/1860201-gilead-vs-johnson-johnson-roche-in-blood-cancer-showdown?source=yahoo
-
CLL, competitive landscape. Arzerra er godt med i kombi med ibrutinib og idelalisib https://twitter.com/zDonShimoda/status/405007
519640064000/photo/1/large -
-
ja, det bliver lidt af et landskab at fylde ud. Arzerra + alkylator er ikke taget med i opgørelsen.
-
"
This has made some investors nervous. Michael Yee of RBC Capital Markets speculates that the FDA is waiting for data from the ongoing Resonate trial in January which compares Imbruvica to Arzerra, a drug made by GlaxoSmithKline (GSK)."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind